TransMedics is recognized as a transformative player in organ transplant technology, featuring a unique multi-organ perfusion platform and an integrated logistics network. Despite recent stock pullbacks caused by margin volatility from increased investments, the company presents an attractive long-term investment opportunity. Key growth drivers include the anticipated kidney Organ Care System (OCS) product, potentially submitted to the FDA by 2027, and international market expansion. The company targets over $2 billion in revenue by 2032, with an appealing valuation given its strong revenue growth and margin expansion potential.
As of Sep 26, 2026 19:02 WIB, TransMedics Group Inc (TMDX) trades on Pluang at USD 85.29 with a 1-day gain of 1.66%. The stock shows a market cap of $2.96 billion and an enterprise value of $3.35 billion. Despite a majority of Pluang users selling at 78%, the typical hold time is 23 days, indicating some investors see potential in the stock's future. The most notable figure is the enterprise value of $3.35 billion, highlighting the company's significant market presence.
